JP2004524279A - ピリミジン誘導体、及びニューロペプチドｙ受容体リガンドとしてのその使用 - Google Patents

ピリミジン誘導体、及びニューロペプチドｙ受容体リガンドとしてのその使用 Download PDF

Info

Publication number
JP2004524279A
JP2004524279A JP2002541086A JP2002541086A JP2004524279A JP 2004524279 A JP2004524279 A JP 2004524279A JP 2002541086 A JP2002541086 A JP 2002541086A JP 2002541086 A JP2002541086 A JP 2002541086A JP 2004524279 A JP2004524279 A JP 2004524279A
Authority
JP
Japan
Prior art keywords
methyl
vinyl
phenyl
pyrimidine
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002541086A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004524279A5 (https=
Inventor
ブロイ，フォルカー
ダウツェンベルク，フランク
マタイ，パトリツィオ
ニダール，ヴェルナー
プフリーガー，フィリッペ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2004524279A publication Critical patent/JP2004524279A/ja
Publication of JP2004524279A5 publication Critical patent/JP2004524279A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2002541086A 2000-11-10 2001-11-06 ピリミジン誘導体、及びニューロペプチドｙ受容体リガンドとしてのその使用 Pending JP2004524279A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00124610 2000-11-10
PCT/EP2001/012818 WO2002038551A1 (en) 2000-11-10 2001-11-06 Pyrimidine derivatives and their use as neuropeptide y receptor ligands

Publications (2)

Publication Number Publication Date
JP2004524279A true JP2004524279A (ja) 2004-08-12
JP2004524279A5 JP2004524279A5 (https=) 2005-04-21

Family

ID=8170342

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002541086A Pending JP2004524279A (ja) 2000-11-10 2001-11-06 ピリミジン誘導体、及びニューロペプチドｙ受容体リガンドとしてのその使用

Country Status (20)

Country Link
US (1) US6657060B2 (https=)
EP (1) EP1335906B1 (https=)
JP (1) JP2004524279A (https=)
KR (1) KR100611853B1 (https=)
CN (1) CN1473156A (https=)
AR (1) AR034700A1 (https=)
AT (1) ATE340784T1 (https=)
AU (2) AU2790502A (https=)
BR (1) BR0115045A (https=)
CA (1) CA2427350A1 (https=)
DE (1) DE60123458T2 (https=)
DK (1) DK1335906T3 (https=)
ES (1) ES2271100T3 (https=)
MX (1) MXPA03004136A (https=)
PA (1) PA8531701A1 (https=)
PE (1) PE20020603A1 (https=)
PT (1) PT1335906E (https=)
UY (1) UY27018A1 (https=)
WO (1) WO2002038551A1 (https=)
ZA (1) ZA200302970B (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005520821A (ja) * 2002-03-15 2005-07-14 チバ　スペシャルティ　ケミカルズ　ホールディング　インコーポレーテッド ４−アミノピリミジン及び表面の抗菌処理のためのその使用
JP2008525407A (ja) * 2004-12-24 2008-07-17 アストラゼネカ・ユーケイ・リミテッド 化学的方法
JP2011201873A (ja) * 2010-03-03 2011-10-13 Mitsubishi Tanabe Pharma Corp 三置換ピリミジン化合物及びそのｐｄｅ１０阻害薬としての使用
JP2012501962A (ja) * 2008-09-10 2012-01-26 田辺三菱製薬株式会社 芳香族含窒素六員環化合物及びその使用

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3813152B2 (ja) 2002-03-12 2006-08-23 メルク エンド カムパニー インコーポレーテッド 置換アミド類
US7768604B2 (en) * 2005-09-20 2010-08-03 Au Optronics Corporation Transflective liquid crystal display with partially shifted reflectivity curve
EP1979325A1 (en) * 2006-01-11 2008-10-15 AstraZeneca AB Morpholino pyrimidine derivatives and their use in therapy
GB0616747D0 (en) * 2006-08-24 2006-10-04 Astrazeneca Ab Novel compounds
EP2057129A1 (en) * 2006-08-24 2009-05-13 AstraZeneca AB Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
AU2007287428B2 (en) 2006-08-24 2011-08-11 Astrazeneca Ab Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
CN101809002B (zh) 2007-07-09 2013-03-27 阿斯利康(瑞典)有限公司 用于与mtor激酶和/或pi3k相关的疾病中的吗啉代嘧啶衍生物
BRPI0814503A2 (pt) * 2007-07-09 2017-05-16 Astrazeneca Ab composto, uso de um composto, métodos para produzir um efeito anti-proliferativo em um animal de sangue quente, e para tratar uma doença, e, composição farmacêutica
US20100261723A1 (en) * 2007-07-09 2010-10-14 Astrazeneca Ab Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
AU2008273889B2 (en) * 2007-07-09 2012-03-08 Astrazeneca Ab Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
US20110053923A1 (en) * 2008-12-22 2011-03-03 Astrazeneca Chemical compounds 610
US20130237550A1 (en) * 2010-03-11 2013-09-12 Targacept, Inc. Arylvinylazacycloalkane compounds for constipation
SA111320519B1 (ar) 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
WO2015039292A1 (zh) * 2013-09-18 2015-03-26 华安医学股份有限公司 一种活化ampk的化合物及其用途
CN112375042A (zh) * 2020-10-27 2021-02-19 安徽医科大学 三甲氧基苯乙烯基六元环类和吡唑并嘧啶类化合物、制剂及其制备与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0720467B2 (ja) * 1988-06-15 1995-03-08 松下電器産業株式会社 超音波診断装置
JPH024345A (ja) * 1988-06-15 1990-01-09 Matsushita Electric Ind Co Ltd 超音波変換装置
US5728704A (en) 1992-09-28 1998-03-17 Pfizer Inc. Substituted pyridmidines for control of diabetic complications
US6011039A (en) 1996-03-21 2000-01-04 Banyu Pharmaceutical Co., Ltd. Aminopyridine derivatives
AU6309698A (en) * 1997-03-12 1998-09-29 Banyu Pharmaceutical Co., Ltd. Drugs containing aminopyridine derivatives as the active ingredient

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005520821A (ja) * 2002-03-15 2005-07-14 チバ　スペシャルティ　ケミカルズ　ホールディング　インコーポレーテッド ４−アミノピリミジン及び表面の抗菌処理のためのその使用
JP2008525407A (ja) * 2004-12-24 2008-07-17 アストラゼネカ・ユーケイ・リミテッド 化学的方法
JP2012501962A (ja) * 2008-09-10 2012-01-26 田辺三菱製薬株式会社 芳香族含窒素六員環化合物及びその使用
JP2011201873A (ja) * 2010-03-03 2011-10-13 Mitsubishi Tanabe Pharma Corp 三置換ピリミジン化合物及びそのｐｄｅ１０阻害薬としての使用

Also Published As

Publication number Publication date
CA2427350A1 (en) 2002-05-16
PA8531701A1 (es) 2003-06-30
DK1335906T3 (da) 2007-02-05
ATE340784T1 (de) 2006-10-15
AU2002227905B2 (en) 2006-10-05
AU2790502A (en) 2002-05-21
KR20040004432A (ko) 2004-01-13
EP1335906A1 (en) 2003-08-20
DE60123458T2 (de) 2007-08-02
DE60123458D1 (de) 2006-11-09
UY27018A1 (es) 2002-06-20
CN1473156A (zh) 2004-02-04
MXPA03004136A (es) 2003-08-19
PE20020603A1 (es) 2002-07-20
BR0115045A (pt) 2004-02-03
AR034700A1 (es) 2004-03-17
ZA200302970B (en) 2004-07-15
WO2002038551A1 (en) 2002-05-16
EP1335906B1 (en) 2006-09-27
ES2271100T3 (es) 2007-04-16
KR100611853B1 (ko) 2006-08-11
PT1335906E (pt) 2007-01-31
US20020086858A1 (en) 2002-07-04
US6657060B2 (en) 2003-12-02

Similar Documents

Publication Publication Date Title
JP2004524279A (ja) ピリミジン誘導体、及びニューロペプチドｙ受容体リガンドとしてのその使用
TW520362B (en) Substituted pyrimidine compounds and pharmaceutical composition comprising same
US6335340B1 (en) compounds of heteroaryl substituted imidazole, their pharmaceutical compositons and uses
US5811549A (en) Process of preparing imidazole compounds
US7265125B2 (en) Neuropeptide Y antagonists
US6509361B1 (en) 1,5-Diaryl substituted pyrazoles as p38 kinase inhibitors
AU2002227905A1 (en) Pyrimidine derivatives and their use as neuropeptide Y receptor ligands
US6469018B1 (en) Compounds
JP2002507992A (ja) 新規な置換イミダゾール化合物
JP2002508780A (ja) 新規な化合物
JP2002514196A (ja) 置換ピリミジノンおよびピリドン化合物ならびに使用方法
JPH10512555A (ja) サイトカインとして有用なある種の１，４，５−三置換イミダゾール化合物
TW200418478A (en) Novel pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them
JP5237115B2 (ja) 新規複素環類
KR100647932B1 (ko) 퀴나졸린 유도체
TW201730183A (zh) 作爲磷酸二酯酶抑制劑之新穎經取代之吲哚啉化合物
JPH11514641A (ja) 新規なピペラジニルアルキルチオピリミジン誘導体、それを含有する製薬学的組成物およびその新規化合物の製法
JPH0447671B2 (https=)
US20110015395A1 (en) Pyrazole compounds with inhibitory activity against ros kinase
JP3167700B1 (ja) ２，３−ジアリール−ピラゾロ［１，５−ｂ］ピリダジン誘導体、その製造方法およびそのシクロオキシゲナーゼ２（ｃｏｘ−２）阻害剤としての使用
HK1030211A (en) 3(5)-heteroaryl substituted pyrazoles as p38 kinase inhibitors

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070116

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20070619